Long-Term Assets: The sum of all assets classified as non-current.
Theravance Biopharma, Inc. (TBPH) had Long-Term Assets of $59.74M for the most recently reported fiscal quarter, ending 2025-06-30.
Income Statement Financials | |
$26.20M |
|
$54.84M |
|
-- |
|
$26.20M |
|
$28.92M |
|
$-2.73M |
|
$75.93M |
|
$73.21M |
|
$-1.93M |
|
$54.84M |
|
$54.84M |
|
$54.84M |
|
$-39.16M |
|
$-2.73M |
|
$-2.74M |
|
50.18M |
|
50.73M |
|
$1.09 |
|
$1.08 |
|
Balance Sheet Financials | |
$366.29M |
|
$6.64M |
|
Long-Term Assets |
$59.74M |
$426.04M |
|
$54.63M |
|
-- |
|
$146.55M |
|
$201.19M |
|
$224.85M |
|
$224.85M |
|
$224.85M |
|
50.36M |
|
Cash Flow Statement Financials | |
$251.11M |
|
$-5.63M |
|
$-1.36M |
|
$38.63M |
|
$282.76M |
|
$244.13M |
|
$9.42M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
6.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-10.40% |
|
-10.40% |
|
-- |
|
279.47% |
|
209.33% |
|
$251.08M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
1.20 |
|
75.31 |
|
24.39% |
|
24.39% |
|
12.87% |
|
24.39% |
|
$4.46 |
|
$4.95 |
|
$4.95 |